-- 
Amsterdam Molecular Falls as Much as 58% After EMA Decision

-- B y   K r i s t e n   H a l l a m
-- 
2011-10-21T11:55:08Z

-- http://www.bloomberg.com/news/2011-10-21/amsterdam-molecular-falls-as-much-as-58-after-ema-decision.html
Amsterdam Molecular Therapeutics (AMT) 
Holding NV fell as much as 58 percent in Amsterdam trading after
a European Medicines Agency panel said the company’s Glybera
therapy for the genetic disorder disorder lipoprotein lipase
deficiency wasn’t approvable at this time.  To contact the editor responsible for this story:
Kristen Hallam at 
 khallam@bloomberg.net  